Welcome to our dedicated page for Hercules Capital news (Ticker: HTGC), a resource for investors and traders seeking the latest updates and insights on Hercules Capital stock.
Hercules Capital, Inc. (NYSE: HTGC) is a premier specialty finance company dedicated to providing senior secured loans to high-growth, venture capital-backed companies in technology-related markets. Established in December 2003, Hercules has positioned itself as a key player in the venture lending space, committing over $4.6 billion to more than 300 companies across various stages of development. The company focuses on sectors such as technology, biotechnology, life sciences, and sustainable and renewable energy.
Hercules Capital stands out by offering more than just financial support. The company provides vital access to its expansive network of contacts and invaluable business advice, helping entrepreneurial companies achieve significant milestones. Their investment portfolio includes a mix of structured debt with warrants, senior debt, and equity investments.
Recent achievements include a $35 million loan facility to SynOx Therapeutics Limited to support the development of emactuzumab, a next-generation monoclonal antibody for treating Tenosynovial Giant Cell Tumour (TGCT). Another notable investment is the $150 million financing to Harness, a Modern Software Delivery Platform company, to expand its platform with new modules and enhance its use of generative AI.
Hercules Capital’s strategic partnerships and financial solutions make it the lender of choice for venture-backed companies seeking reliable growth capital. The company’s financial stability and extensive industry expertise ensure that it remains a trusted partner for innovation-driven businesses looking to scale.
Corium, Inc. has secured a $235 million term loan from Hercules Capital, Inc. to accelerate the commercialization of its ADHD treatment, AZSTARYS, and advance its pipeline. The loan includes an initial tranche of $100 million, with additional funds contingent on achieving specific milestones. AZSTARYS, approved by the FDA in March 2021, is the first product containing serdexmethylphenidate, aimed at treating ADHD in patients aged 6 and older. This financing reflects Hercules' confidence in Corium's growth potential.
Hercules Capital, Inc. (NYSE: HTGC) has announced a record achievement in its financing activities, originating over $1.5 billion in gross debt and equity commitments year-to-date, surpassing its previous record of $1.47 billion. This milestone reflects the firm's strong market presence and disciplined underwriting approach. The company has also recently completed a public offering of $325 million in 2.625% Notes, enhancing its liquidity and reducing overall debt costs, positioning itself for future investment opportunities.
Hercules Capital, Inc. (NYSE: HTGC) has completed a public offering of $325 million in 2.625% unsecured notes due September 16, 2026. The proceeds will be used to repurchase existing asset-backed notes, fund investments in debt and equity securities, and for general corporate purposes. The Notes, rated Baa3 and BBB+ by Moody's and Kroll Bond Rating Agency respectively, offer semiannual interest payments. Hercules continues to lead in providing growth loans to high-growth, venture-backed companies, having committed over $12 billion since its inception in December 2003.
Hercules Capital, Inc. (NYSE: HTGC) has priced a public offering of $325 million in 2.625% notes due September 2026. The unsecured notes will deliver interest semiannually and can be redeemed at the Company’s option. The net proceeds will be used to repurchase asset-backed notes, fund investments in debt and equity securities, and for general corporate purposes. The offering's completion is subject to customary closing conditions.
Better Therapeutics has secured a loan facility of up to
Hercules Capital, Inc. (NYSE: HTGC) has achieved over $1.0 billion in total debt and equity commitments year-to-date, marking the fourth consecutive year of such performance. CEO Scott Bluestein stated that the company is positioned to surpass its previous record of $1.47 billion in total commitments. The strong performance is attributed to the Technology and Life Sciences teams. Since 2003, Hercules has committed over $12.0 billion to more than 530 companies, making it a preferred financing partner in the venture growth sector.
Hercules Capital (HTGC) reported strong financial results for Q2 2021, achieving 100% coverage of dividend distributions with net investment income (NII) of $37.0 million, or $0.32 per share. Total investments increased to $2.4 billion, with net debt portfolio growth of nearly $57 million. The company maintained strong liquidity with $610 million available. Notably, 26 portfolio companies had exit events, contributing to $160 million in undistributed earnings spillover. However, effective yields decreased to 12.7% and there were net realized losses of $14.3 million this quarter.
Hercules Capital, Inc. (NYSE: HTGC) has announced a supplemental cash distribution of $0.07 per share, to be paid from undistributed taxable income as of June 30, 2021. The distribution will be made on August 18, 2021, with a record date of August 11, 2021. This is in addition to the regular quarterly cash distribution of $0.32 per share for Q2 2021. Hercules aims to distribute approximately 90% to 100% of its taxable income annually. Notably, 87.7% of the Q2 distributions are classified as Qualified Interest Income, possibly exempt from U.S. withholding tax for foreign investors.
Hercules Capital, Inc. (NYSE: HTGC) has announced a cash distribution of $0.32 per share for the second quarter of 2021, with a record date of August 11, 2021 and a payment date of August 18, 2021. The company follows a variable distribution policy aiming to distribute approximately 90% to 100% of its taxable quarterly income. As of the second quarter, 87.7% of the declared distributions are classified as Qualified Interest Income (QII), which may benefit non-U.S. shareholders by being exempt from U.S. withholding tax.
Hercules Capital, Inc. (NYSE: HTGC), the top specialty financing provider, has scheduled its second quarter 2021 financial results conference call for July 29, 2021, at 2:00 p.m. PT. The company will release its financial results after market close on the same day. A live webcast will be available on the investor relations section of Hercules' website, and a replay will be accessible for seven days post-call. Since its inception, Hercules has committed over $11.6 billion to more than 530 companies, focusing on senior secured loans to high-growth, innovative firms.
FAQ
What is the current stock price of Hercules Capital (HTGC)?
What is the market cap of Hercules Capital (HTGC)?
What does Hercules Capital, Inc. specialize in?
Which industries does Hercules Capital, Inc. focus on?
How much has Hercules Capital, Inc. committed since its inception?
What kind of financial products does Hercules Capital, Inc. offer?
Can you provide an example of a recent investment by Hercules Capital, Inc.?
Why do companies choose Hercules Capital, Inc.?
How does Hercules Capital, Inc. support its portfolio companies beyond financial investment?
What is a notable recent achievement of Hercules Capital, Inc.?
How does Hercules Capital, Inc. ensure its financial stability?